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Abstract
Prion infections, causing neurodegenerative conditions such as Creutzfeldt-Jakob disease and kuru in humans, scrapie in
sheep and BSE in cattle are characterised by prolonged and variable incubation periods that are faithfully reproduced in
mouse models. Incubation time is partly determined by genetic factors including polymorphisms in the prion protein gene.
Quantitative trait loci studies in mice and human genome-wide association studies have confirmed that multiple genes are
involved. Candidate gene approaches have also been used and identified App, Il1-r1 and Sod1 as affecting incubation times.
In this study we looked for an association between App, Il1-r1 and Sod1 representative SNPs and prion disease incubation
time in the Northport heterogeneous stock of mice inoculated with the Chandler/RML prion strain. No association was seen
with App, however, significant associations were seen with Il1-r1 (P = 0.02) and Sod1 (P,0.0001) suggesting that
polymorphisms at these loci contribute to the natural variation observed in incubation time. Furthermore, following
challenge with Chandler/RML, ME7 and MRC2 prion strains, Sod1 deficient mice showed highly significant reductions in
incubation time of 20, 13 and 24%, respectively. No differences were detected in Sod1 expression or activity. Our data
confirm the protective role of endogenous Sod1 in prion disease.
Citation: Akhtar S, Grizenkova J, Wenborn A, Hummerich H, Fernandez de Marco M, et al. (2013) Sod1 Deficiency Reduces Incubation Time in Mouse Models of
Prion Disease. PLoS ONE 8(1): e54454. doi:10.1371/journal.pone.0054454
Editor: Jiyan Ma, Ohio State University, United States of America
Received November 19, 2012; Accepted December 11, 2012; Published January 22, 2013
Copyright:  2013 Akhtar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by the UK Medical Research Council (www.mrc.ac.uk). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: JC is a director and shareholder of D-Gen limited, an academic spin-out company in the field of prion diagnosis, decontamination and
therapeutics. This does not alter the authors’ adherence to all the PLOS One policies on sharing data and materials.
* E-mail: s.lloyd@prion.ucl.ac.uk
Introduction
Prion diseases or transmissible spongiform encephalopathies
(TSEs) are progressive neurodegenerative diseases which are
invariably fatal. They include Creutzfeldt-Jakob disease (CJD) in
humans, bovine spongiform encephalopathy in cattle (BSE) and
scrapie in sheep and goats [1]. They are transmissible misfolded
protein diseases caused by the conversion of normal cellular prion
protein (PrPC) to abnormal isoforms, known as PrPSc. In addition
to PrPSc accumulation they are characterised by spongiform
vacuolation, gliosis and neuronal loss in the brain.
Prion disease incubation time in experimental mouse models is
remarkably consistent if experimental parameters are kept
constant, however, there is considerable variation between
different inbred strains of mice suggesting a strong genetic
contribution. The prion protein gene, Prnp, is the major
component where homozygous knockout mice are completely
resistant to prion propagation and disease, hemizygous knockout
mice have a prolonged incubation time and PrP overexpressors
have a much shorter incubation time than wild type mice [2,3].
Incubation time is also modulated by a naturally occurring
polymorphisms in Prnp where Prnpa (108-Leu, 189-Thr) and Prnpb
(108-Phe, 189-Val) are associated short and long incubation times
respectively [4–8]. Similarly, a methionine to valine polymorphism
at codon 129 of human PrP is also a major susceptibility factor for
human prion disease [9–13]. Most inbred lines of mice are Prnpa
and within these there is still considerable variation in incubation
time thus implicating other genes [14]. Quantitative trait loci study
in mice [15–19] and genome-wide association studies (GWAS) in
humans [13,20] suggest that although Prnp is the single most
important factor, the combined effect of several other genes are
also of importance.
In addition to traditional mapping techniques, individual
candidate gene approaches have also been employed to identify
genes that influence prion disease incubation time. Twenty
candidate genes were screened based on pathways and genes
previously implicated in prion disease by testing knockout or
transgenic mouse models [21]. Under these conditions, most genes
had no effect on incubation time, however, knockout of App
(amyloid precursor protein), Il1-r1 (interleukin 1 receptor 1) and
overexpression of human SOD1 (superoxide dismutase 1) increased
survival by 13, 16 and 19% respectively.
To test whether App, Il1-r1 and Sod1 contribute to the naturally
occurring variation in inbred lines of mice we used a heterogenous
stock (HS) of mice inoculated with the Chandler/Rocky Mountain
Laboratory (RML) mouse-adapted scrapie prion strain to look for
a statistical association between prion disease incubation time and
these genetic loci [22–25]. The Sod1 locus produced a highly
significant association therefore we investigated this further by
challenging Sod1 deficient mice (Sod12/2) with three different
prion strains.
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Materials and Methods
Ethics Statement
All procedures were conducted in accordance with institutional,
UK and international regulations and standards on animal welfare
and conform to ARRIVE guidelines [26]. Ethical approval was
granted by the Medical Research Council (MRC) Prion Unit
ethics committee and carried out under UK Home Office licence
PPL70/7274.
Mice
Northport HS mice (Gift from R. Hitzemann, Portland,
Oregon, USA) were bred and prion incubation times were
collected for mice at generation 37 (n= 1052) as previously
described [22]. Sod1 knockout mice (B6;129S7-Sod1tm1Leb/J) were
obtained from the Jackson Laboratory (Bar Harbor, Maine, USA)
and backcrossed to C57BL/6J to .N7 (Gift from EMC Fisher,
University College London Institute of Neurology, London, UK)
[27]. The resulting heterozygote animals (Sod12/+) were inter-
crossed to provide homozygote knockouts (Sod12/2) and wild type
litter mate controls (Sod1+/+). Other inbred mouse lines were
provided by Harlan, UK Ltd. (Bicester, UK).
Prion Inoculation and Phenotyping
Inocula were made from the brains of terminally sick mice as
1% (weight/volume) homogenates in D-PBS. The Chandler/
RML (I9900), ME7 (I9459) and MRC2 (I9468) prion strains were
sourced and prepared as previously described [22,28]. Mice were
anaesthetized with isofluorane/O2 and inoculated intra-cerebrally
into the right parietal lobe with 30 ml of inocula as previously
described [15]. To minimise animal suffering, mice were
examined daily for clinical signs of prion disease and were culled
once a definitive diagnosis had been made or earlier if showing any
signs of distress or other health problems. Mice were killed by
exposure to carbon dioxide gas in rising concentration. Criteria for
defining scrapie in mice were as previously described [29].
Incubation time was defined as the number of days from
inoculation to diagnosis. All procedures were conducted in
accordance with institutional, UK and international regulations
and standards on animal welfare and conform to ARRIVE
guidelines [26]. Ethical approval was granted by the MRC Prion
Unit ethics committee and carried out under UK Home Office
licence PPL70/7274.
PCR and Sequencing
DNA for each of the heterogeneous stock parental lines was
obtained from the Jackson Laboratory (Bar Harbor, Maine, USA).
PCR and sequencing reactions were carried out as previously
described [23] and run on a 3730 capillary sequencer (Applied
Biosystems).
Genotyping
DNA was extracted from the HS cross mice as previously
described [23]. SNP genotyping was carried out using the Allelic
Discrimination function on a 7500 Fast Real-time PCR machine
(Applied Biosystems) using RoxMegaMix Gold (Microzone, Ltd)
as previously described [23]. Primers and probes are shown in
Table S1.
Real-time RT-PCR
Whole brain RNA was extracted from uninfected (6–8 weeks
old) mice and reverse transcribed using AMV reverse transcriptase
and random primers as previously described [29]. Control
reactions were carried out with no reverse-transcription for each
sample to ensure no genomic DNA contamination of the RNA
preparation. Real-time RT-PCR reactions were carried out on a
7500 Fast Real-time PCR System (Applied Biosystems) as
previously described [29]. Sod1 Taqman Gene Expression assay
(Life Technologies) was duplexed with each of three endogenous
controls (GAPDH, b-actin and Thy-1) [23]. All reactions were
carried out in triplicate. All data passed a normality test and was
statistically evaluated using a t-test.
Western Blotting
For detection of PrPSc by western blotting 10% (weight/volume)
brain homogenates in D-PBS were prepared by ribolysing.
Samples were benzonase treated and proteinase K digested
(50 mg/ml of proteinase K for 1 h at 37uC) and blotted as
described previously [30]. PrP was detected with anti-PrP
monoclonal antibody ICSM35 (D-Gen Ltd, UK) [31] and
alkaline-phosphatase-conjugated anti-mouse IgG secondary anti-
body (Sigma-Aldrich) developed in the chemiluminescent substrate
CDP-Star (Tropix Inc). For detection of Sod1, samples were
prepared as above but without proteinase K digestion and
detected with a rabbit polyclonal antibody (0.5 ug/ml) (Abcam).
Anti-b-actin mouse monoclonal antibody (0.05 ug/ml) (Sigma)
was used as an internal control as previously described [28].
Immunohistochemistry
Mouse brains were fixed in 10% buffered formal saline (BFS)
and prion infected tissue was treated in 98% formic acid for one
hour to remove infectivity. Tissues were paraffin wax embedded,
sectioned and stained as previously described [29]. Sections were
stained with haematoxylin and eosin (H&E) for general viewing
including assessment of spongiosis and neuronal loss. Disease
associated prion deposition was visualised with anti-PrP monoclo-
nal antibody ICSM35 (D-Gen Ltd, UK) and gliosis was
determined with an anti-glial fibrillary acid protein (GFAP)
antibody (Dako Ltd, UK).
Quantification of PrPc
10% (weight/volume) brain homogenates were used to measure
endogenous levels of PrPc by enzyme linked immunosorbent assay
(ELISA) as previously described [32]. Total protein concentration
was measured using a Pierce BCA protein assay kit (Thermo
Scientific) according to the manufacturer’s instructions.
Superoxide Dismutase Enzymatic Activity Assay
Total SOD activity was measured in 10% weight/volume
(20 mM HEPES, pH 7.2, 1 mM EGTA, 210 mM mannitol,
70 mM sucrose) brain homogenates using a SOD assay kit
(Calbiochem) according to the Manufacturer’s instructions. A
Coomassie (Bradford) protein assay kit (Bio-Rad) was used to
measure the total protein concentration according to the
manufacturer’s instructions.
Statistical Analysis
Statistical tests were carried out using GraphPad InStat
(GraphPad Software, Inc, California, USA) and SPSS (IBM).
The Kaplan-Meier log-rank test was used to analyse survival data.
Results
Association Studies
To look for an association between App, Il1-r1, Sod1 and prion
disease incubation time we used the Northport HS of mice as
Sod1 and Mouse Prion Disease
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previously described [22,23,25,33]. The stock was generated from
eight parental lines (A/J, AKR/J, BALB/cJ, C3H/HeJ, C57BL/
6J, CBA/J, DBA/2J and LP/J) and n= 1052 mice from
generation 37 were inoculated with the Chandler/RML mouse
adapted scrapie prion strain [22].
Inbred lines of mice are closely related, however, it is expected
that multiple single nucleotide polymorphism (SNPs) will be
present between the parental lines of the HS mice. To select the
most advantageous SNPs for genotyping we sequenced the coding
region, untranslated regions (UTR), putative promoters (as
predicted by PROSCAN (www-bimas.cit.nih.gov/molbio/pros-
can) and flanking intronic sequence. From this data we defined the
major strain distribution pattern (SDP) across the parental lines.
This was subsequently confirmed by comparison with genomic
sequencing data SNPs generated by the Sanger Institute (www.
sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps.pl) which
covered the entire gene starting from 5 kb upstream of the
59UTR. The main SDP for each locus and the total number of
SNPs is shown in table 1. To capture each SDP, one tagging SNP
was chosen for genotyping (Table 2). For one SDP of App and Il1-
r1, SNPs were chosen based on putative functional significance
(GCF binding site and amino acid change respectively). Other
SNPs were chosen based on their ability to tag the SDP.
Genotyping was carried out in approximately 400 mice repre-
senting the extremes of the incubation time distribution as this
captures most of the power of the cross [25]. For details of primers
and probes see Table S1. For App, two SNPs were tested,
representing two SDPs (Tables 1 and 2). rs47601325 is located in
the promoter within a GCF binding site (PROSCAN) and
rs46934600 is within intron 2 and is not known to be a functional
variant. Neither of these SNPs showed an association with
incubation time (Table 2). One non-synonymous Il1-r1 coding
polymorphism (Ala71Val) from exon 3 (Table 2) was tested and
this showed a significant association with incubation period
(P = 0.02, Kruskal-Wallis non-parametric ANOVA) where the
CC genotype was associated with a short incubation time
(14461.6, mean (days) 6 sem) and the TT genotype with a
longer incubation time (15563.3). The heterozygous allele CT
was not significantly different from CC (14561.7) suggesting a
dominant mode of action. An allelic test (Mann-Whitney) also
showed a significant association (P= 0.007, C allele 14461.0 and
T allele 14961.4) (Table 2). A Sod1 SNP from intron 3 (Table 2),
of no known function, also showed a highly significant association
with prion disease incubation time (P,0.0001, Kruskal-Wallis
non-parametric ANOVA) where the GG genotype was associated
with a short incubation time (132+4.7) and the AA genotype with a
longer incubation time (149+1.5). In contrast to Il1-r1, the Sod1
alleles appear to behave in an additive way with the heterozygous
allele GA having an intermediate mean incubation time
(14161.8). The allelic test (Mann-Whitney) also showed a highly
significant association (P,0.0001, G allele 14061.7 and A allele
14761.0) (Table 2).
Sod1 mRNA Expression
Based on the association study data Il1-r1 and Sod1 loci are
associated with prion disease incubation time, however, Sod1 has
the strongest effect with a mean difference of 17 days between the
homozygous genotypes compared to 11 days for the Il1-r1
genotypes, therefore, we only followed up the Sod1 data. No
known functional polymorphisms were found in the HS parental
strains for Sod1 and so we measured Sod1 mRNA expression levels
in uninfected brains from the parental lines of the HS (except LP)
to see whether endogenous expression level was associated with
genotype. Sod1 mRNA expression levels were quantified using real
time RT-PCR. Although variation between the inbred lines was
seen (Figure 1A), when grouped by Sod1 genotype (A=A, BALB,
C3H, C57; G=AKR, CBA, DBA) this was not significant
(Figure 1B). We also saw no difference in Sod1 protein expression
by western blot between A and G allele mice either in uninfected
or Chandler/RML infected mice (Figure 1C–D).
Transmission of Prions to Sod12/2 Mice
It was previously reported that overexpression of human SOD1
in a transgenic mouse model increased prion disease incubation
time with the RML prion strain, however, this was not replicated
with the 301 V (BSE passaged in Prnpb allele mice, B6.I) strain
[21]. These transmissions were carried out in small groups (n = 4
or 5), on a mixed genetic background and in the presence of a
foreign protein, therefore, to clarify the role of Sod1 we
transmitted three different prion strains to Sod1 deficient mice.
We used Sod1 knockout mice B6;129S7-Sod1tm1Leb/J backcrossed
to C57BL/6J (Sod12/2) and their litter mates (Sod1+/+) as wild type
controls [27]. Although mutations in human SOD1 are associated
with familial amyotrophic lateral sclerosis (fALS), Sod1 deficient
mice are neurologically normal and do not develop spontaneous
neurodegenerative disease. The only phenotype associated with
these mice is female sterility in homozygote knockouts [27]. We
inoculated mice intracerebrally with two different mouse-adapted
scrapie prion strains, Chandler/RML and ME7, and a mouse
adapted BSE prion strain, MRC2 (BSE passaged in Prnpa mice)
[28,34]. In Sod12/2 mice a significant decrease in incubation time
was seen for all three prion strains as compared to Sod1+/+ controls
(Figure 2 and Table S2). For Chandler/RML prions the mean
incubation time (days 6 sem) was reduced by 20% from 15661 in
Sod1+/+ to 12561 in Sod12/2 mice (P,0.0001, Kaplan-Meier log
rank survival) and for ME7 the mean incubation time was reduced
by 13% from 16462 in Sod1+/+ to 14265 in Sod12/2 mice
(P,0.0001, Kaplan-Meier log rank survival). For MRC2 the mean
incubation time was reduced by 24% from 17862 in Sod1+/+ to
13667 in Sod12/2 mice (P,0.0001, Kaplan-Meier log rank
survival). These data were obtained using female mice, however,
similar results were also recorded for male mice although the mean
differences were reduced to 16, 5 and 13% for Chandler/RML,
ME7 and MRC2 prion strains respectively (Table S2).
Prion strains can be differentiated by biochemical differences in
PrPSc or by patterns of neuropathology in recipient animals.
Western blotting of brains from infected animals confirmed that
there is no change to the PrPSc type caused by replication in the
absence of Sod1 (Figure 3). Pathological evaluation was carried out
Table 1. Major strain distribution patterns genotyped for HS
mice.
Genes Allele and strain distribution pattern SNPs
Sod A= (A, BALB, C3H, C57, LP); G = (AKR, CBA, DBA) 15/15
App C= (A, C3H, DBA); G = (AKR, BALB, C57, CBA, LP) 413/978
C = (A, BALB, C3H, CBA, DBA); T = (AKR, C57, LP) 303/978
Il1-r1 C= (A, AKR, BALB, C57, C3H, CBA, DBA); T = (LP) 70/81
The number of SNPs is taken from genomic sequence generated by the Sanger
Institute (www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps.pl) and
spans 5 kb upstream of the 59UTR start site to the end of the 39UTR (NCBI Build
37). Ambiguous SNPs have been excluded. The strain distribution pattern
(BALB, CBA); (A, AKR, C3H, C57, DBA, LP) was also seen for App (239/978) but
this was not genotyped in the HS mice. Other individual strain distribution
patterns were seen #5 times.
doi:10.1371/journal.pone.0054454.t001
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on brain sections from Sod12/2 and Sod1+/+ mice for each
transmission with particular attention to PrPSc deposition,
spongiosis, gliosis and neuronal loss (Figure 4, Figures S1 and
S2). For Chandler/RML transmission, the pattern of gliosis and
PrPSc staining is similar, however, PrPSc staining is patchier for the
Sod12/2 particularly in the cortex. No hippocampal neuronal loss
Table 2. SNP genotyping in HS mice.
Gene SNP Genotypic test Allelic test
p-value (n) p-value
Sod1 Inron 3 A/G Chr16 90,224,725 ,0.0001 (386) ,0.0001
App Promoter C/G rs47601325 Chr16 85,174,122 0.12 (406) 0.85
App Intron 2 C/T rs46934600 Chr16 85,103,728 0.92 (411) 0.92
Il1-1r Exon 3 Ala71Val C/T Chr1 40,350,109 0.02 (416) 0.01
Genomic location is given based on mouse genome assembly NCBI build 37. Details of the Sod1 and Il1-r1 SNPs are available from the Sanger Centre (www.sanger.ac.
uk/cgi-bin/modelorgs/mousegenomes/snps.pl). All polymorphisms were analysed by allele discrimination using a 7500 Fast real time PCR system (Applied Biosystems).
For probe details see Table S1. For all genotypes, the statistical test used was the Kruskal-Wallis non-parametric ANOVA. The allelic test used was the Mann-Whitney test.
doi:10.1371/journal.pone.0054454.t002
Figure 1. Sod1 expression in mouse brain. Panel A and B. Quantification of Sod1 mRNA expression in whole brain by real-time RT-PCR. N= 6 for
all groups and samples were run in triplicate. All samples were duplexed for Sod1 (Fam-label) and an endogenous control GAPDH, b-actin or Thy-1
(Vic-label). Expression level is expressed in arbitrary units as normalised by the geometric mean of the quantity of the endogenous controls (y-axis).
Error bars represent the standard deviation. (A) Sod1 mRNA expression level for parental strain of the HS mice (except LP). (B) Sod1 mRNA expression
level grouped by allele (A/G) (A =A, BALB, C3H, C57; G =AKR, CBA, DBA). No significant difference was observed between the groups. Panels (C) and
(D). Quantification of Sod1 protein in whole brain (10% homogenate, weight/volume) from n=3 A allele mice (C57Bl/6) and G allele mice (FVB/N).
FVB/N mice were used to represent a G allele strain rather than an HS parental strain due to availability of tissue. Samples were immunoblotted with
rabbit polyclonal anti-human SOD1(Abcam) and detected with IRDye800CW (green) conjugated goat anti-rabbit IgG (Li-Cor). Anti-b-actin mouse
monoclonal antibody (Sigma) was also included as a loading control and was detected using IRDye680 (red) conjugated goat anti-mouse IgG (Li-Cor).
Fluorescence was visualised using an Odyssey infra-red imager (Li-Cor). (C) Uninoculated mice, (D) Terminally sick Chandler/RML prion inoculated
mice.
doi:10.1371/journal.pone.0054454.g001
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is seen in Sod12/2 mice while mild neuronal loss is seen in wild
type animals. No differences are seen between the two groups of
mice following ME7 infection. For MRC2 transmission there is no
difference in the pattern of gliosis and PrPSc deposition, however,
there is a reduced intensity of staining especially in the cortex
stripe in the Sod12/2 mice as compared to wild type. Neuronal loss
in the hippocampus is very variable for the MRC2 transmissions,
however, there is no clear difference between the two groups of
mice.
We have shown that variation at the Sod1 locus is associated
with prion disease incubation time and that this is not explained by
differences in mRNA expression levels. We therefore looked at
Sod1 protein levels by western blot in Sod1+/+ control mice
infected with Chandler/RML, ME7 and MRC2 prions and
compared these with age matched controls (PBS inoculated mice).
No differences were seen between the four groups (Figure 5A). We
also confirmed that the Sod12/2 mice used in these experiments
did not express any detectable Sod1 protein (Figure 5B). Although
the amount of Sod1 appears the same in uninfected and infected
mice it is possible that Sod enzymes are more active in the
environment created by prion infection. We therefore measured
total Sod enzymatic activity in Sod1+/+ mice infected with each of
three prion strains and compared these to uninfected animals. No
significant differences were seen between the groups (Figure 5C).
In experimental mouse models the level of PrPc expression has a
profound effect on incubation time therefore it is possible that the
reduction in incubation time observed in Sod12/2 mice could be
the result of an upregulation of the endogenous levels of PrPc [2,3].
We tested this by measuring total PrPc levels in a PrP specific
ELISA in Sod12/2 and Sod1+/+ mice [32]. No significant
difference was observed (Figure 5D).
Discussion
Quantitative trait loci mapping in mice and GWAS in human
have confirmed that multiple genes in addition to Prnp influence
prion disease incubation time and susceptibility [13,15,17,18,20].
These studies have successfully identified candidate loci but no
individual genes have yet been confirmed as functionally
significant. Alternative strategies have included targeting genes
from pathways implicated in prion disease and testing them
directly in mouse models. This identified App, Il1-r1 and Sod1 as
interesting candidates, however, it did not address whether or not
they contributed to the natural variation [21]. In this study we
carried out an association study for each of these genes in HS of
mice. The mapping resolution available in the HS cross at
generation 37 is approximately 1–2 cM which is too big to
Figure 2. Kaplan-Meier survival curves. Data are shown as % of
animals (female) surviving (y-axis) plotted against the number of days
post inoculation (x-axis). (A) Transmission of Chandler/RML prion strain
to Sod12/2 and Sod1+/+ (WT) litter mate controls (B) Transmission of
ME7 prion strain to Sod12/2 and Sod1+/+ (WT). (C) Transmission of MRC2
mouse adapted BSE prion strain to Sod12/2 and Sod1+/+ (WT). A
reduction in mean incubation time of 20%, 13%, and 24% was seen in
A-C respectively. This reduction in survival was statistically significant
for each transmission (P,0.001, Kaplan-Meier log-rank survival test).
doi:10.1371/journal.pone.0054454.g002
Figure 3. Western blots of PrPSc from infected mouse brains.
10% w/v brain homogenates (n = 3 per group) were digested with
proteinase K and immunoblotted with anti-PrP monoclonal antibody
ICSM35 (D-Gen Ltd, UK). (A) Transmission of Chandler/RML prions to
Sod12/2 and Sod1+/+ (WT) litter mate controls. (B) Transmission of ME7
prion strain to Sod12/2 and Sod1+/+ (WT) litter mate controls. (C)
Transmission of MRC2 mouse adapted BSE prion strain to Sod12/2 and
Sod1+/+ (WT) litter mate controls. No differences were seen between the
two groups regardless of prion strain.
doi:10.1371/journal.pone.0054454.g003
Sod1 and Mouse Prion Disease
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unambiguously ascribe an association to one gene although
mapping to SDPs may help to narrow down the region [25].
App is a very promising candidate gene particularly given its
involvement in Alzheimer’s disease (AD), a neurodegenerative
protein misfolding disease. There is also increasing evidence for an
interaction with PrP where PrP has been implicated in post-
translational processing of APP through the inhibition of BACE1
and in some mouse models PrP may bind amyloid-b and mediate
aspects of its neurotoxicity [35–38]. Despite its attractions as a
candidate we did not find any evidence of an association with
prion disease incubation time in this cross although it is possible
that other SDPs not tested by us may show some association. App
may still have a role in prion disease although it does not appear to
contribute to the natural variation observed in the parental lines of
this cross.
Il1-r1 is a receptor for the pro-inflammatory cytokine, Il-1,
produced by glia and implicated in the disease process as a result
of extensive gliosis. Il1-r1 knockout mice have been previously
studied confirming that deletion of Il1-r1 is protective in models of
mouse scrapie [21,39]. In this study we identify a non-synonymous
SNP (Ala71Val) on a SDP that is linked to prion disease
incubation time. It is not clear whether this SNP is the functional
variant or whether it is carried within the same haplotype block.
Sod1 is an ubiquitously expressed cytoplasmic superoxide
dismutase that protects cells from oxidative damage by removing
superoxide through converting it to hydrogen peroxide. It has
been associated with other neurodegenerative diseases notably
amyotrophic lateral sclerosis where mutations in human SOD1
account for ,20% of familial ALS cases probably via a toxic gain
of function [40]. Sod1 has also been implicated in Alzheimer’s
disease whereby Sod1 knockout accelerated amyloid-b oligomer-
isation and memory loss in an AD mouse model and conversely
overexpression of Sod1 rescues the cerebral endothelial dysfunc-
tion in another AD model [41,42]. In this study we have shown a
highly significant association with the Sod1 locus and prion disease
incubation time thereby confirming its effect on the natural
variation within these inbred lines of mice. The functional SNPs
remain unknown and we have not detected any evidence for
differential mRNA or protein expression. We have also confirmed
the role of Sod1 as a protective factor in prion disease as deletion
of Sod1 significantly reduces incubation time in two different
strains of mouse adapted scrapie (Chandler/RML and ME7) and
a mouse passaged BSE prion strain, MRC2. These data broadly
agree with previously published data that suggested a protective
effect of overexpressing human SOD1 in mice challenged with
RML but not 301 V prions [21]. This difference may be explained
by the presence of the human protein or by differences in the
mouse adapted BSE strains caused by passage in Prnpb rather than
Prnpa mice. We cannot exclude the possibility that the targeted
knockout of Sod1 in these mice may inadvertently affect the
expression of adjacent loci which themselves influence prion
disease incubation time and that this would explain the absence of
detectable differences in Sod1 expression.
Oxidative stress has been implicated in neurodegenerative
diseases and is caused by excess reactive oxygen species such as
superoxide accumulating with the cell which may be the result of
excess production by malfunctioning mitochondria and depletion
of catalytic enzymes. In mouse models of prion disease damaged
mitochondria have been described as well as evidence for
increased superoxide generation and free radical damage
[43,44]. Markers of oxidative damage have also been described
in CJD brains [45]. We did not detect a change in Sod1 protein
expression or total Sod activity in response to prion infection with
any of our prion strains, however, the presence of normal Sod1
activity is clearly protective as Sod1 deficient mice show a
significantly reduced incubation time across all prion strains tested.
Figure 4. RML histology. Histological features of Chandler/RML prion transmission to Sod12/2 (A–C) and wild type control (D–F) mice. Panels A
and D show distribution of disease-associated PrP by immunohistochemistry using anti-PrP monoclonal antibody ICSM35. Panels B, C, E and F show
detail from the hippocampus and are stained with haematoxylin and eosin (H&E) to visualise spongiform change and neuronal loss. There is almost
no neuronal loss in the Sod12/2 mice but mild neuronal loss is seen in the wild type animals. Overall, the pattern of spongiosis, gliosis and PrP
distribution are similar between the two groups, however, the distribution of disease-associated PrP is patchier in the knockouts especially in the
cortex. Scale bar corresponds to 3 mm (A, D), 660 mm (B, E) or 160 mm (C, F).
doi:10.1371/journal.pone.0054454.g004
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Conclusion
In conclusion, we have shown that both Il1-r1 and Sod, but not
App, are associated with the natural variation in prion disease
incubation time measured in the Northport HS mice. In addition,
Sod1 deficient mice show highly significant reductions in
incubation time of 20, 13 and 24% with Chandler/RML, ME7
and MRC2 prion strains, respectively. Although no differences in
Sod1 expression or activity were detected our data highlight the
importance of oxidative damage in prion disease and the
protective role played by endogenous Sod1 protein.
Supporting Information
Figure S1 ME7 histology. Histological features of ME7 prion
transmission to Sod12/2 (A–C) and wild type control (D–F) mice.
Panels A and D show PrPSc distribution by staining with anti-PrP
monoclonal antibody ICSM35. Panels B, C, E and F show detail
from the hippocampus and are stained with haematoxylin and
eosin (H&E) to visualise spongiform change and neuronal loss. No
differences are seen between the two groups. Scale bar
corresponds to 3 mm (A, D), 660 mm (B, E) or 160 mm (C, F).
(TIF)
Figure S2 MRC2 histology. Histological features of MRC2
prion transmission to Sod12/2 (A–C) and wild type control (D–F)
mice. Panels A and D show PrPSc distribution by staining with
anti-PrP monoclonal antibody ICSM35. Panels B, C, E and F
show detail from the hippocampus and are stained with
haematoxylin and eosin (H&E) to visualise spongiform change
and neuronal loss. Sod12/2 mice (D) show a reduction in PrP
intensity relative to wild type mice especially in the cortex stripe.
Scale bar corresponds to 3 mm (A, D), 660 mm (B, E) or 160 mm
(C, F).
(TIF)
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